Vasculitis & polymyalgia rheumatica
Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study
Authors' conclusion
LEF and ADA had comparable outcomes after a median of 15.0 months of follow-up. However, withdrawal from therapy and mild-to-moderate adverse events were only observed in the LEF group.
Study context
- Population
- Adults (≥18 years) with TAK fulfilling the 2022 ACR/EULAR classification criteria, with relapsing/refractory disease or toxicity from previous therapy
- Participants
- 44 adults
- Exposure
- ADA vs leflunomide (LEF)
- ADAn = 16
- LEFn = 28reference
- Outcome
- Complete response rate
- Follow-up
- 15.0 months (T2)
Methodological detailspropensity score matching (sensitivity adjustment)
- Propensity score matching (sensitivity adjustment)
Main finding
As reported in the abstract
T2 (15.0 months)
P = 0.307
Observational data: associations, not effects.
Further findings
Complete response rate · T1 (median 7.0 months)
P = 0.397
Angiographic progression
P = 0.467
Median daily prednisone dose · T1 and T2
- Higher in ADA at T1 (p=0.004)
- Similar at T2 (p=0.595)
Safety
- Mild-to-moderate adverse events — LEF
- 17.9%
Mild-to-moderate adverse events
- Observed only in the LEF group
Original publication
Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study. RMD Open. Published 4 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →